Table 3.

Most frequently reported grade 3 or higher AEs (in more than 10% of patients) by preferred term occurring in arm A or arm B

AEArm A
CPX-351 plus venetoclax (N = 27)
Arm B
CPX-351 plus midostaurin (N = 23)
Patients with any grade ≥3 AE, n (%) 25 (93) 23 (100) 
Patients with grade ≥3 hematologic AE, n (%) 
Febrile neutropenia 17 (63) 16 (70) 
Thrombocytopenia 12 (44) 15 (65) 
Leukopenia 11 (41) 14 (61) 
Neutropenia 10 (37) 9 (39) 
Anemia 5 (19) 8 (35) 
Lymphopenia 3 (11) 
Patients with grade ≥3 nonhematologic AE, n (%) 
Hypokalemia 3 (11) 1 (4) 
Hypoxia 3 (11) 1 (4) 
Sepsis 3 (11) 1 (4) 
Syncope 3 (11) 
Pneumonia 2 (7) 4 (17) 
AEArm A
CPX-351 plus venetoclax (N = 27)
Arm B
CPX-351 plus midostaurin (N = 23)
Patients with any grade ≥3 AE, n (%) 25 (93) 23 (100) 
Patients with grade ≥3 hematologic AE, n (%) 
Febrile neutropenia 17 (63) 16 (70) 
Thrombocytopenia 12 (44) 15 (65) 
Leukopenia 11 (41) 14 (61) 
Neutropenia 10 (37) 9 (39) 
Anemia 5 (19) 8 (35) 
Lymphopenia 3 (11) 
Patients with grade ≥3 nonhematologic AE, n (%) 
Hypokalemia 3 (11) 1 (4) 
Hypoxia 3 (11) 1 (4) 
Sepsis 3 (11) 1 (4) 
Syncope 3 (11) 
Pneumonia 2 (7) 4 (17) 

All AEs were coded using Medical Dictionary for Regulatory Activities, version 21.1. Severity grade was coded using Common Terminology Criteria for Adverse Events, version 5.0. Multiple entries for an individual patient under each preferred term were only counted once.

or Create an Account

Close Modal
Close Modal